Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVS NASDAQ:PVLA NASDAQ:TRDA NYSE:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$6.16+7.5%$4.69$2.54▼$10.00$459.01M0.52524,354 shs1.12 million shsPVLAPalvella Therapeutics$55.68+2.8%$39.37$11.17▼$58.22$615.82M-0.03124,112 shs173,449 shsTRDAEntrada Therapeutics$5.29+1.3%$6.06$4.93▼$21.79$201.22M-0.13211,500 shs347,742 shsVNRXVolitionRx$0.60-5.2%$0.68$0.40▼$0.94$64.77M1.27196,345 shs363,642 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals+7.50%+7.32%+47.72%+57.54%+51.72%PVLAPalvella Therapeutics+2.84%+2.83%+42.51%+119.21%+5,567,999,900.00%TRDAEntrada Therapeutics+1.34%-3.29%-11.09%-36.42%-65.65%VNRXVolitionRx-5.94%-12.75%-9.88%+8.66%-14.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$6.16+7.5%$4.69$2.54▼$10.00$459.01M0.52524,354 shs1.12 million shsPVLAPalvella Therapeutics$55.68+2.8%$39.37$11.17▼$58.22$615.82M-0.03124,112 shs173,449 shsTRDAEntrada Therapeutics$5.29+1.3%$6.06$4.93▼$21.79$201.22M-0.13211,500 shs347,742 shsVNRXVolitionRx$0.60-5.2%$0.68$0.40▼$0.94$64.77M1.27196,345 shs363,642 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals+7.50%+7.32%+47.72%+57.54%+51.72%PVLAPalvella Therapeutics+2.84%+2.83%+42.51%+119.21%+5,567,999,900.00%TRDAEntrada Therapeutics+1.34%-3.29%-11.09%-36.42%-65.65%VNRXVolitionRx-5.94%-12.75%-9.88%+8.66%-14.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVSCorvus Pharmaceuticals 3.00Buy$15.00143.51% UpsidePVLAPalvella Therapeutics 3.09Buy$58.505.06% UpsideTRDAEntrada Therapeutics 3.00Buy$25.67385.19% UpsideVNRXVolitionRx 3.00Buy$3.50481.40% UpsideCurrent Analyst Ratings BreakdownLatest VNRX, TRDA, CRVS, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $66.008/15/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $75.008/15/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $60.008/15/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/8/2025TRDAEntrada TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/5/2025PVLAPalvella TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$54.008/4/2025PVLAPalvella TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$90.007/21/2025PVLAPalvella TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$56.007/17/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/9/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/10/2025VNRXVolitionRxJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$3.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVSCorvus PharmaceuticalsN/AN/AN/AN/A$0.51 per shareN/APVLAPalvella Therapeutics$42.81M14.38N/AN/A$5.58 per share9.98TRDAEntrada Therapeutics$210.78M0.95$1.59 per share3.33$11.46 per share0.46VNRXVolitionRx$1.32M49.10N/AN/A($0.11) per share-5.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVSCorvus Pharmaceuticals-$62.29M-$1.01N/AN/AN/AN/A-28.61%-18.05%11/11/2025 (Estimated)PVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-62.30%-43.34%11/12/2025 (Estimated)TRDAEntrada Therapeutics$65.63M-$1.78N/AN/AN/A-92.30%-17.81%-14.55%11/4/2025 (Estimated)VNRXVolitionRx-$35.32M-$0.25N/A∞N/A-2,321.14%N/A-163.39%N/ALatest VNRX, TRDA, CRVS, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PVLAPalvella Therapeutics-$0.78-$0.86-$0.08-$0.86N/AN/A8/7/2025Q2 2025CRVSCorvus Pharmaceuticals-$0.13-$0.10+$0.03-$0.10N/AN/A8/6/2025Q2 2025TRDAEntrada Therapeutics-$0.86-$1.04-$0.18-$1.04$8.17 million$1.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVSCorvus PharmaceuticalsN/A8.918.91PVLAPalvella TherapeuticsN/A7.677.67TRDAEntrada TherapeuticsN/A18.6418.64VNRXVolitionRxN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVSCorvus Pharmaceuticals46.64%PVLAPalvella Therapeutics40.11%TRDAEntrada Therapeutics86.39%VNRXVolitionRx8.09%Insider OwnershipCompanyInsider OwnershipCRVSCorvus Pharmaceuticals28.50%PVLAPalvella Therapeutics20.50%TRDAEntrada Therapeutics8.11%VNRXVolitionRx10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVSCorvus Pharmaceuticals3074.51 million53.28 millionOptionablePVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/ATRDAEntrada Therapeutics11038.04 million34.95 millionOptionableVNRXVolitionRx80107.60 million80.80 millionOptionableVNRX, TRDA, CRVS, and PVLA HeadlinesRecent News About These CompaniesZacks Small Cap Estimates VolitionRx Q3 EarningsAugust 29, 2025 | marketbeat.comAnalysts Offer Predictions for VolitionRx Q3 EarningsAugust 29, 2025 | americanbankingnews.comQ3 Earnings Forecast for VolitionRx Issued By HC WainwrightAugust 22, 2025 | marketbeat.comHC Wainwright Has Negative Outlook of VolitionRx Q4 EarningsAugust 21, 2025 | marketbeat.comD. Boral Capital Reiterates "Buy" Rating for VolitionRx (NYSE:VNRX)August 17, 2025 | marketbeat.comVolitionRx Limited (AMEX:VNRX) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comVolitionRx Limited (VNRX) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | seekingalpha.comVolitionRx reports Q2 revenue $400K, consensus $375.72KAugust 14, 2025 | msn.comVolitionRx Limited Announces Second Quarter 2025 Financial Results and Business UpdateAugust 14, 2025 | prnewswire.comInsights into VolitionRX's Upcoming EarningsAugust 14, 2025 | benzinga.comVolitionRx (NYSE:VNRX) Stock Price Down 4.3% - Here's What HappenedAugust 9, 2025 | marketbeat.comVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update | ...August 8, 2025 | gurufocus.comVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business UpdateAugust 8, 2025 | prnewswire.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 78,125 Shares of StockAugust 7, 2025 | marketbeat.comCameron John Reynolds Buys 78,125 Shares of VolitionRx Limited (NYSE:VNRX) StockAugust 7, 2025 | marketbeat.comVolitionRx Limited (NYSE:VNRX) Director Acquires $50,000.00 in StockAugust 7, 2025 | insidertrades.comVolitionRx Announces Pricing of $1.2 Million Registered Direct OfferingAugust 4, 2025 | prnewswire.comNu.Q® Discover Expands Global Adoption and Epigenetic InnovationJuly 16, 2025 | prnewswire.comVolitionRx Limited (VNRX) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comVolition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of NucleosomesJuly 8, 2025 | prnewswire.comVolition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ FailureJune 12, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVNRX, TRDA, CRVS, and PVLA Company DescriptionsCorvus Pharmaceuticals NASDAQ:CRVS$6.16 +0.43 (+7.50%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.12 -0.04 (-0.57%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Palvella Therapeutics NASDAQ:PVLA$55.68 +1.54 (+2.84%) As of 09/5/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Entrada Therapeutics NASDAQ:TRDA$5.29 +0.07 (+1.34%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.30 +0.01 (+0.19%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.VolitionRx NYSE:VNRX$0.60 -0.03 (-5.18%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$0.60 0.00 (0.00%) As of 09/5/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
